Richard Schilsky to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications Richard Schilsky has written about Clinical Trials, Phase II as Topic.
Connection Strength
0.213
-
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009 Apr 20; 27(12):2091-6.
Score: 0.079
-
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25.
Score: 0.031
-
Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014 Aug 20; 32(24):2587-94.
Score: 0.029
-
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20; 32(12):1277-80.
Score: 0.028
-
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993 Oct 20; 85(20):1637-43.
Score: 0.028
-
FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol. 2007 Mar; 14(3):330-9.
Score: 0.017